GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today, Synageva BioPharma Corp's share price is $238.60. Synageva BioPharma Corp's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2015 was $-5.27. Hence, Synageva BioPharma Corp's Price-to-Free-Cash-Flow Ratio for today is .
During the past 13 years, Synageva BioPharma Corp's highest Price-to-Free-Cash-Flow Ratio was 79.59. The lowest was 0.00. And the median was 6.58.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.50% per year.
During the past 13 years, Synageva BioPharma Corp's highest 3-Year average Free Cash Flow per Share Growth Rate was 68.30% per year. The lowest was 0.00% per year. And the median was 2.55% per year.
Synageva BioPharma Corp's Price-to-Free-Cash-Flow ratio for today is calculated as
|Price-to-Free-Cash-Flow Ratio||=||Share Price||/||Free Cash Flow per Share (TTM)|
Synageva BioPharma Corp's Share Price of today is $238.60.
Synageva BioPharma Corp's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2015 was -1.25 (Jun. 2014 ) + -1.37 (Sep. 2014 ) + -1.3 (Dec. 2014 ) + -1.35 (Mar. 2015 ) = $-5.27.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, managements decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data